Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity

被引:61
作者
Mori, Yutaka
Itoh, Yohta
Tajima, Naoko
机构
[1] Utsunomiya Natl Hosp, Natl Hosp Org, Dept Internal Med, Kawachi, Tochigi 3291193, Japan
[2] Jikei Univ, Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Tokyo, Japan
关键词
telmisartan; adipocyte; insulin resistance; hypertriglyceridemia;
D O I
10.1016/j.amjhyper.2006.09.016
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Objective: To investigate the influence of blockade of the renin-angiotensin system (RAS) on adipocytes, we compared the effect of telmisartan versus valsartan and amlodipine on adipocyte cellularity in the spontaneously type 2 diabetic, obese rat model. Methods: Male Otsuka Long Evans Tokushima Fatty rats, 8-week-old, were divided into four groups as follows: valsartan (V) group (10 mg/kg, n = 12), telmisartan (T) group (5 mg/kg, n = 12), amlodipine (A) group (2 mg/kg, n = 12), and control (C) group (n = 12). Each drug was mixed with chow and given for 16 weeks. Results: Although no significant differences were observed in the fasting plasma glucose level between the groups, the fasting plasma insulin level for group T was significantly lower than that for group C. Histopathologic examination showed that the ratio of small adipocytes in groups V and T was significantly higher than that in group C, with the ratio of large adipocytes and the mean adipocyte size shown to be significantly lower in groups V and T than in group C. Furthermore, group T was shown to have a significantly higher ratio of small adipocytes, a significantly lower ratio of large adipocytes, as well as a significantly lower mean adipocyte size, compared to group V. Conclusions: Although both valsartan and telmisartan downsized adipocytes, adipocyte downsizing was significantly greater with telmisartan compared to valsartan. The likely mechanism for this difference was thought to be the PPAR-gamma-mediated action of telmisartan.
引用
收藏
页码:431 / 436
页数:6
相关论文
共 27 条
  • [1] Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice
    Araki, Kana
    Masaki, Takayuki
    Katsuragi, Isao
    Tanaka, Katsuhiro
    Kakuma, Tetsuya
    Yoshimatsu, Hironobu
    [J]. HYPERTENSION, 2006, 48 (01) : 51 - 57
  • [2] Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity
    Benson, SC
    Pershadsingh, HA
    Ho, CI
    Chittiboyina, A
    Desai, P
    Pravenec, M
    Qi, NN
    Wang, JM
    Avery, MA
    Kurtz, TW
    [J]. HYPERTENSION, 2004, 43 (05) : 993 - 1002
  • [3] Renal function in the AT1A receptor knockout mouse during normal and volume-expanded conditions
    Cervenka, L
    Mitchell, KD
    Oliverio, MI
    Coffman, TM
    Navar, LG
    [J]. KIDNEY INTERNATIONAL, 1999, 56 (05) : 1855 - 1862
  • [4] FOLCH J, 1957, J BIOL CHEM, V226, P497
  • [5] Furuhashi M, 2004, J HYPERTENS, V22, P1977, DOI 10.1097/00004872-200410000-00021
  • [6] Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia
    Hikita, M
    Bujo, H
    Yamazaki, K
    Taira, K
    Takahashi, K
    Kobayashi, J
    Saito, Y
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 277 (02) : 423 - 429
  • [7] WHICH IS THE PRIMARY ETIOLOGIC EVENT IN OTSUKA LONG-EVANS TOKUSHIMA FATTY RATS, A MODEL OF SPONTANEOUS NON-INSULIN-DEPENDENT DIABETES-MELLITUS, INSULIN-RESISTANCE, OR IMPAIRED INSULIN-SECRETION
    ISHIDA, K
    MIZUNO, A
    MIN, Z
    SANO, T
    SHIMA, K
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (07): : 940 - 945
  • [8] Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors
    Iwaki, M
    Matsuda, M
    Maeda, N
    Funahashi, T
    Matsuzawa, Y
    Makishima, M
    Shimomura, I
    [J]. DIABETES, 2003, 52 (07) : 1655 - 1663
  • [9] Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors
    Janke, J
    Engeli, S
    Gorzelniak, K
    Luft, FC
    Sharma, AM
    [J]. DIABETES, 2002, 51 (06) : 1699 - 1707
  • [10] Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Julius, S
    Kjeldsen, SE
    Weber, M
    Brunner, HR
    Ekman, S
    Hansson, L
    Hua, TS
    Laragh, J
    McInnes, GT
    Mitchell, L
    Plat, F
    Schork, A
    Smith, B
    Zanchetti, A
    [J]. LANCET, 2004, 363 (9426) : 2022 - 2031